CARL ZEISS MEDITEC AG - BR (AFX.DE) Stock Fundamental Analysis
Europe - Frankfurt Stock Exchange - FRA:AFX - DE0005313704 - Common Stock
39.98 EUR
-0.1 (-0.25%)
Taking everything into account, AFX scores 5 out of 10 in our fundamental rating. AFX was compared to 65 industry peers in the Health Care Equipment & Supplies industry. AFX has an average financial health and profitability rating. AFX has a correct valuation and a medium growth rate.
1. Profitability
1.1 Basic Checks
AFX had positive earnings in the past year.
In the past year AFX had a positive cash flow from operations.
Each year in the past 5 years AFX has been profitable.
Each year in the past 5 years AFX had a positive operating cash flow.
1.2 Ratios
AFX's Return On Assets of 4.15% is in line compared to the rest of the industry. AFX outperforms 60.00% of its industry peers.
Looking at the Return On Equity, with a value of 6.67%, AFX is in line with its industry, outperforming 50.77% of the companies in the same industry.
The Return On Invested Capital of AFX (5.79%) is comparable to the rest of the industry.
Measured over the past 3 years, the Average Return On Invested Capital for AFX is below the industry average of 9.71%.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.15% | ||
| ROE | 6.67% | ||
| ROIC | 5.79% |
ROA(3y)6.33%
ROA(5y)7.85%
ROE(3y)9.62%
ROE(5y)11.54%
ROIC(3y)7.11%
ROIC(5y)9.66%
1.3 Margins
The Profit Margin of AFX (6.34%) is comparable to the rest of the industry.
In the last couple of years the Profit Margin of AFX has declined.
The Operating Margin of AFX (10.03%) is comparable to the rest of the industry.
AFX's Operating Margin has declined in the last couple of years.
With a Gross Margin value of 52.76%, AFX perfoms like the industry average, outperforming 41.54% of the companies in the same industry.
In the last couple of years the Gross Margin of AFX has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.03% | ||
| PM (TTM) | 6.34% | ||
| GM | 52.76% |
OM growth 3Y-21.67%
OM growth 5Y-5.49%
PM growth 3Y-25.69%
PM growth 5Y-7.11%
GM growth 3Y-3.8%
GM growth 5Y-1.12%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so AFX is still creating some value.
AFX has about the same amout of shares outstanding than it did 1 year ago.
The number of shares outstanding for AFX has been reduced compared to 5 years ago.
Compared to 1 year ago, AFX has an improved debt to assets ratio.
2.2 Solvency
An Altman-Z score of 3.45 indicates that AFX is not in any danger for bankruptcy at the moment.
AFX's Altman-Z score of 3.45 is fine compared to the rest of the industry. AFX outperforms 66.15% of its industry peers.
The Debt to FCF ratio of AFX is 4.41, which is a neutral value as it means it would take AFX, 4.41 years of fcf income to pay off all of its debts.
AFX has a Debt to FCF ratio (4.41) which is comparable to the rest of the industry.
A Debt/Equity ratio of 0.27 indicates that AFX is not too dependend on debt financing.
AFX's Debt to Equity ratio of 0.27 is in line compared to the rest of the industry. AFX outperforms 60.00% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.27 | ||
| Debt/FCF | 4.41 | ||
| Altman-Z | 3.45 |
ROIC/WACC0.86
WACC6.72%
2.3 Liquidity
AFX has a Current Ratio of 2.35. This indicates that AFX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.35, AFX is in the better half of the industry, outperforming 69.23% of the companies in the same industry.
AFX has a Quick Ratio of 1.44. This is a normal value and indicates that AFX is financially healthy and should not expect problems in meeting its short term obligations.
AFX has a Quick ratio of 1.44. This is in the better half of the industry: AFX outperforms 72.31% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.35 | ||
| Quick Ratio | 1.44 |
3. Growth
3.1 Past
AFX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -19.90%.
The Earnings Per Share has been growing slightly by 3.28% on average over the past years.
AFX shows a small growth in Revenue. In the last year, the Revenue has grown by 7.82%.
Measured over the past years, AFX shows a quite strong growth in Revenue. The Revenue has been growing by 10.78% on average per year.
EPS 1Y (TTM)-19.9%
EPS 3Y-21.2%
EPS 5Y3.28%
EPS Q2Q%-14.49%
Revenue 1Y (TTM)7.82%
Revenue growth 3Y5.39%
Revenue growth 5Y10.78%
Sales Q2Q%8.27%
3.2 Future
AFX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 20.13% yearly.
Based on estimates for the next years, AFX will show a small growth in Revenue. The Revenue will grow by 6.97% on average per year.
EPS Next Y27.78%
EPS Next 2Y25.05%
EPS Next 3Y26.27%
EPS Next 5Y20.13%
Revenue Next Year4.86%
Revenue Next 2Y6.03%
Revenue Next 3Y6.88%
Revenue Next 5Y6.97%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 24.83, which indicates a rather expensive current valuation of AFX.
AFX's Price/Earnings ratio is a bit cheaper when compared to the industry. AFX is cheaper than 67.69% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.39, AFX is valued at the same level.
The Price/Forward Earnings ratio is 19.43, which indicates a rather expensive current valuation of AFX.
61.54% of the companies in the same industry are more expensive than AFX, based on the Price/Forward Earnings ratio.
AFX is valuated at similar levels of the S&P average when we compare the Price/Forward Earnings ratio to 23.84, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 24.83 | ||
| Fwd PE | 19.43 |
4.2 Price Multiples
76.92% of the companies in the same industry are more expensive than AFX, based on the Enterprise Value to EBITDA ratio.
Based on the Price/Free Cash Flow ratio, AFX is valued a bit cheaper than the industry average as 69.23% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 26.83 | ||
| EV/EBITDA | 11.71 |
4.3 Compensation for Growth
AFX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as AFX's earnings are expected to grow with 26.27% in the coming years.
PEG (NY)0.89
PEG (5Y)7.57
EPS Next 2Y25.05%
EPS Next 3Y26.27%
5. Dividend
5.1 Amount
With a Yearly Dividend Yield of 1.38%, AFX has a reasonable but not impressive dividend return.
AFX's Dividend Yield is a higher than the industry average which is at 1.03.
Compared to the average S&P500 Dividend Yield of 1.87, AFX is paying slightly less dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.38% |
5.2 History
The dividend of AFX decreases each year by -1.59%.
Dividend Growth(5Y)-1.59%
Div Incr Years1
Div Non Decr Years4
5.3 Sustainability
37.19% of the earnings are spent on dividend by AFX. This is a low number and sustainable payout ratio.
DP37.19%
EPS Next 2Y25.05%
EPS Next 3Y26.27%
FRA:AFX (12/22/2025, 4:00:17 PM)
39.98
-0.1 (-0.25%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners25.58%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap3.58B
Revenue(TTM)2.23B
Net Income(TTM)141.22M
Analysts73.64
Price Target55.56 (38.97%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 1.38% |
Yearly Dividend0.6
Dividend Growth(5Y)-1.59%
DP37.19%
Div Incr Years1
Div Non Decr Years4
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-21.46%
Min EPS beat(2)-33.88%
Max EPS beat(2)-9.05%
EPS beat(4)1
Avg EPS beat(4)-16.59%
Min EPS beat(4)-36.67%
Max EPS beat(4)13.25%
EPS beat(8)4
Avg EPS beat(8)-3.62%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)0.89%
Min Revenue beat(2)-1.14%
Max Revenue beat(2)2.92%
Revenue beat(4)3
Avg Revenue beat(4)1.59%
Min Revenue beat(4)-1.14%
Max Revenue beat(4)3.76%
Revenue beat(8)5
Avg Revenue beat(8)-0.32%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0.25%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-0.61%
EPS NY rev (3m)-8.19%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-0.04%
Revenue NY rev (3m)-0.17%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 24.83 | ||
| Fwd PE | 19.43 | ||
| P/S | 1.61 | ||
| P/FCF | 26.83 | ||
| P/OCF | 17.04 | ||
| P/B | 1.69 | ||
| P/tB | 7.39 | ||
| EV/EBITDA | 11.71 |
EPS(TTM)1.61
EY4.03%
EPS(NY)2.06
Fwd EY5.15%
FCF(TTM)1.49
FCFY3.73%
OCF(TTM)2.35
OCFY5.87%
SpS24.91
BVpS23.66
TBVpS5.41
PEG (NY)0.89
PEG (5Y)7.57
Graham Number29.28
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 4.15% | ||
| ROE | 6.67% | ||
| ROCE | 7.81% | ||
| ROIC | 5.79% | ||
| ROICexc | 5.89% | ||
| ROICexgc | 14.08% | ||
| OM | 10.03% | ||
| PM (TTM) | 6.34% | ||
| GM | 52.76% | ||
| FCFM | 5.98% |
ROA(3y)6.33%
ROA(5y)7.85%
ROE(3y)9.62%
ROE(5y)11.54%
ROIC(3y)7.11%
ROIC(5y)9.66%
ROICexc(3y)7.22%
ROICexc(5y)9.75%
ROICexgc(3y)13.97%
ROICexgc(5y)15.82%
ROCE(3y)9.59%
ROCE(5y)13.04%
ROICexgc growth 3Y-8.4%
ROICexgc growth 5Y5.55%
ROICexc growth 3Y-23.03%
ROICexc growth 5Y-5.34%
OM growth 3Y-21.67%
OM growth 5Y-5.49%
PM growth 3Y-25.69%
PM growth 5Y-7.11%
GM growth 3Y-3.8%
GM growth 5Y-1.12%
F-Score6
Asset Turnover0.65
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.27 | ||
| Debt/FCF | 4.41 | ||
| Debt/EBITDA | 1.61 | ||
| Cap/Depr | 60.61% | ||
| Cap/Sales | 3.44% | ||
| Interest Coverage | 10.38 | ||
| Cash Conversion | 60% | ||
| Profit Quality | 94.37% | ||
| Current Ratio | 2.35 | ||
| Quick Ratio | 1.44 | ||
| Altman-Z | 3.45 |
F-Score6
WACC6.72%
ROIC/WACC0.86
Cap/Depr(3y)109.66%
Cap/Depr(5y)110.76%
Cap/Sales(3y)5.42%
Cap/Sales(5y)4.92%
Profit Quality(3y)64.92%
Profit Quality(5y)71.29%
High Growth Momentum
Growth
EPS 1Y (TTM)-19.9%
EPS 3Y-21.2%
EPS 5Y3.28%
EPS Q2Q%-14.49%
EPS Next Y27.78%
EPS Next 2Y25.05%
EPS Next 3Y26.27%
EPS Next 5Y20.13%
Revenue 1Y (TTM)7.82%
Revenue growth 3Y5.39%
Revenue growth 5Y10.78%
Sales Q2Q%8.27%
Revenue Next Year4.86%
Revenue Next 2Y6.03%
Revenue Next 3Y6.88%
Revenue Next 5Y6.97%
EBIT growth 1Y14.86%
EBIT growth 3Y-17.44%
EBIT growth 5Y4.69%
EBIT Next Year73.64%
EBIT Next 3Y32.77%
EBIT Next 5Y23.51%
FCF growth 1Y40.11%
FCF growth 3Y7.85%
FCF growth 5Y-0.04%
OCF growth 1Y-15.15%
OCF growth 3Y3.7%
OCF growth 5Y3.29%
CARL ZEISS MEDITEC AG - BR / AFX.DE FAQ
What is the fundamental rating for AFX stock?
ChartMill assigns a fundamental rating of 5 / 10 to AFX.DE.
Can you provide the valuation status for CARL ZEISS MEDITEC AG - BR?
ChartMill assigns a valuation rating of 4 / 10 to CARL ZEISS MEDITEC AG - BR (AFX.DE). This can be considered as Fairly Valued.
Can you provide the profitability details for CARL ZEISS MEDITEC AG - BR?
CARL ZEISS MEDITEC AG - BR (AFX.DE) has a profitability rating of 4 / 10.
What is the valuation of CARL ZEISS MEDITEC AG - BR based on its PE and PB ratios?
The Price/Earnings (PE) ratio for CARL ZEISS MEDITEC AG - BR (AFX.DE) is 24.83 and the Price/Book (PB) ratio is 1.69.
What is the financial health of CARL ZEISS MEDITEC AG - BR (AFX.DE) stock?
The financial health rating of CARL ZEISS MEDITEC AG - BR (AFX.DE) is 6 / 10.